SCHEMBL13302575

SCHEMBL13302575

[2H]C([2H])([2H])n1c(C(N)(C([2H])([2H])[2H])C([2H])([2H])[2H])nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNE1 P15382 1/20 0.55
CCR1 P32246 1/20 0.55
KCNQ1 P51787 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.46
ERCC1 P07992 1/20 0.45
FEN1 P39748 1/20 0.45
ERCC4 Q92889 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
LIPG Q9Y5X9 1/20 0.44
KCNH2 Q12809 1/20 0.44
CYP2C9 P11712 1/20 0.44
SCD O00767 1/20 0.41
CALCA P06881 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1151004 0.89 KCNE1 (0.65) KCNE1CCR1KCNQ1SMN1; SMN2ERCC1
Water SCHEMBL20885818 0.88 KCNE1 (0.64) KCNE1CCR1KCNQ1SMN1; SMN2ERCC1
SCHEMBL5314622 0.82 KCNE1 (0.67) KCNE1CCR1KCNQ1SMN1; SMN2ERCC1
SCHEMBL4905094 0.80 KCNE1 (0.65) KCNE1CCR1KCNQ1SMN1; SMN2ERCC1
SCHEMBL13041229 0.79 KCNE1 (0.69) KCNE1CCR1KCNQ1SMN1; SMN2ERCC1
SCHEMBL13302579 0.79 KCNE1 (0.53) KCNE1CCR1KCNQ1SMN1; SMN2ERCC1
Raltegravir SCHEMBL13302573 0.79 KCNE1 (0.83) KCNE1CCR1KCNQ1SMN1; SMN2ERCC1
SCHEMBL1150537 0.78 KCNE1 (0.74) KCNE1CCR1KCNQ1SMN1; SMN2ERCC1
SCHEMBL5315124 0.78 KCNE1 (0.66) KCNE1CCR1KCNQ1SMN1; SMN2ERCC1
SCHEMBL19306601 0.78 KCNE1 (0.75) KCNE1CCR1KCNQ1SMN1; SMN2ERCC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318754-B2 Pyrimidinecarboxamide derivatives CONCERT PHARMACEUTICALS INC. (US) 2012-11-27 US disclosed
US-20100152214-A1 NOVEL PYRIMIDINECARBOXAMIDE DERIVATIVES CONCERT PHARMACEUTICALS INC. (US) 2010-06-17 US disclosed
US-7687509-B2 Pyrimidinecarboxamide derivatives CONCERT PHARMACEUTICALS INC. (US) 2010-03-30 US disclosed
US-20090035324-A1 NOVEL PYRIMIDINECARBOXAMIDE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035324-A1 NOVEL PYRIMIDINECARBOXAMIDE DERIVATIVES TYMP, PNP, DPYD KCNE1 3599/4885CCR1 2270/4885KCNQ1 3893/4885
US-20100152214-A1 NOVEL PYRIMIDINECARBOXAMIDE DERIVATIVES TYMP, PNP, DPYD KCNE1 3599/4885CCR1 2270/4885KCNQ1 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.